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[571 ABSTRACT 
In accordance with the present invention. biologically active 
protein fragments can be constructed which contain only 
those specific portions of the serum albumin family of 
proteins such as regions known as subdomains ItA and IIL4 
which are primarily responsible for the binding properties of 
the serum albumins. The artificial serums that can be pre- 
pared from these biologically active protein fragments are 
advantageous in that they can be produced much more easily 
than serums containing the whole albumin. yet s t i l l  retain all 
or most of the original binding potential of the full albumin 
proteins. In addition. since the protein fragment serums of 
the present invention can be made from non-natural s o u r ~ ~ s  
using conventional recombinant DNA techniques, they are 
far safer than serums containing natural albumin because 
they do not cany the potentially harmful viruses and other 
contaminants that will be found in the natural substances. 
11 Claims, 4 Drawing Sheets 
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BIOLOGICALLY ACTIVE PROTEIN 
FRAGMENTS CONTAINING SPECIFIC 
BINDING REGIONS OF SERUM ALBUMIN 
OR RELATED PROTEINS 
sources. Unfortunately. at present, the numerous concerns 
with regard to the safety of albumin-containing plasma 
isolated from natural sources have greatly restricted the 
availability of albumin proteins for many of these applica- 
5 tions. Included among these concerns is the heightened 
possibility that the plasma from which the albumins are 
obtained will be infected with various viral contaminants 
including HIV or other AIDS-related viruses, Hepatitis-B, 
herpes. and a number of other potentially pathogenic micro- 
Because of these concerns. there have been many attempts 
to Prepare recombinant DNA sequences coding for Serum 
albumins which can be used in the artificial production of 
this important molecule. However, unfortunately. these 
15 attempts have also been generally unsuccessful because of 
the fact that like most large proteins. serum albumins 
The Serum albumins belong to a multigene family of denature quite readily and are practically impossible to 
proteins that includes alpha-fetopotein and human produce in usable quantities by genetic engineering. It thus 
group-spec~c component ( G ~ )  or ,,-binding p r ~  has remained a problem to develop artificial serum solutions 
tein. The members of this mdtigene family are typically 20 which are stable and which can maintain the biologically 
comprised of relatively large multi-domain proteins, and the 
serum albumins are major soluble protein constituents of the clearly. the utility of the serum albumin molecules is 
circulatory system which have m y  physiological func- based in large part in their ability to bind and thus transport 
tions. The albumins and their related voteins contribute a wide variety of important macromolecules so as to regulate 
significantly to colloid osmotic blood pressure and aid in the 25 a number of physiological functions in humans and animals. 
transport. distribution and metabolism of many endogenous However. althou& the binding Properties of serum albumin 
and exogenous ligands. These ligan& represent a spectrum have been well-established, the precise nature and location 
of chemically diverse molecules. including fatty acids. of those binding regions have not. Thus, although certain 
amino acids (notably tryptophan and cysteine). steroids. amino acid sites. such as Lys 199 and 411 have been 
metals such as calcium, copper and zinc, and numerous 30 identified as involved in acetylation (see Hagag et d., 
pharmaceuticals. They are thought to f ad ta t e  transfer of Biochemistry 22:2420 (1983)) and esterification (see Sol- 
many ligands across organ-circulatory interfaces such as the lene et d., Molec. Pharmac. 14:754 (1979)). very little has 
liver. intestine. kidney and brain. and evidence suggests the been Previously been known about the binding sites of the 
existence of an albumin cell surface receptor (see Schnitzer 35 serum albumins. 
et al., PNAS 85:6773 (1988)). There has thus been a long-felt and unfulfilled need in the 
In addition. Serum albumins are also found in tissues a d  art to identify specific binding sites in the serum albumin 
secreted fluids throughout the body. For example, it is family of proteins so as to allow the large-scale production 
estimated that albumin in evascular protein co+ses 60% of protein fragments having the same binding properties and 
of the body’s total albumin. In humans. human Serum 4o biological activity as whole serum albumins. Since such 
albumin, or HSA. is a protein of about 65,000 daltons in smaller genetically engineered polypeptides are much more 
molecular weight and contains 585 amino acids. Its amino easily expressed and produced in large quantities than the 
acid sequence contains a total of 17 disulphide bridges. one full albumins. the identification of these specific binding 
free thiol (Cys 34). and a single tryptophan (l‘q 214). The sites would make commercial isolation and production of 
disulphides are positioned in a repeating series of nine 45 artificial polypeptides having all of the same binding prop- 
loop-link-loop structures centered around eight sequential erties of natural albumins much more economically and 
c y s e s  pairs. technically feasible. 
This application is a continuation of application Ser. No. 
08/024.547. filed Mar. 1, 1993, now abandoned. 
FIELD OF THE INVENTION 
serum albumin and related proteins and to biologically 
active protein fragments containing these specific binding 
regions that can be safely and economically produced using 
conventional recombinant DNA techniques. 
The invention relates to the specific binding regions of lo organisms* 
BACKGROUND OF THE INVENTION 
Of natural serum albumins. 
Studies of serum albumins have been made on a variety 
of animal species. and it has been determined that approxi- 
mately 61% of the amino acid sequences are conserved 
among the known sequences of bovine. rat and human serum 
albumins. More recently, additional sequences for the albu- 
mins have been determined with regard to a wide ranging 
group of vertebrates including sheep. frog. salmon. mouse, 
pig and even sea lampreys. Most of these proteins share high 
sequence homology and al l  of them share the characteristic 
repeating series of disulphide bridges. AU members of the 
albumin multigene family for which sequences have been 
determined have internal sequence homology (from two- to 
seven-fold). suggesting that the proteins evolved from a 
common ancestral protein of possibly about 190 amino 
acids. Other studies have confirmed this homology (see, e.g., 
Carter et al.. Science 244:1195 (1989)). 
Currently, there are literally thousands of applications for 
serum albumin protein and its related proteins, Gc and AFT, 
and most often these applications have used the native serum 
albumin family of proteins obtained from bovine or human 
SUMMARY OF THE INvENTlON 
In accordance with the present invention, it has now been 
discovered that specific portions of the semm albumin 
multigene family of proteins. specifically those portions 
known as subdomains IIA and IIl.4. are primarily respon- 
sible for the binding properties of serum albumin and its 
55 related proteins. and that biologically active artificial serums 
prepared from protein fragments containing at least one of 
these binding regions can be produced much more easily 
than serums containing the whole protein. In particular. the 
sequence for binding subdomain IIA appears to be from 
60 about amino acids 190 through 300 on the albumin 
molecules, and subdomain EL4 appears to be located on the 
polypeptide at roughly from amino acid 380 to about amino 
acid 495. 
Further. it also appears that a fusion product. which 
65 includes not only the above binding subdomains ILA and 
IIIA but an additional region IlB. is also useful in binding, 




amino acid 190 through 495. The discovery that the binding 
of the albumin family of proteins is based primarily on these 
specific binding regions will thus allow for the production of 
protein fragments containing one or more of these binding 
regions which are capable of exhibiting the same biological 
activity as the whole albumin protein. 
It is thus an object of the present invention to provide 
protein fragments containing at least one of the binding sites 
from the serum albumin family of proteins so as to allow the 
production of biologically active serum which does not 
contain albumin family proteins obtained from natural 
sources. 
It is further an object of the present invention to provide 
novel artificial polypeptides which can be constructed using 
conventional recombinant DNA techniques and which can 
be more safely. economically and effectively used in a 
variety of applications which call for serum albumins or 
other related proteins. 
It is even further an object of the present invention to 
construct biologically active protein fragments that are use- 
ful for a wide variety of physiological, chromatographic and 
crystallographic functions which can be produced in large 
quantities and which can effectively be used instead of 
whole serum albumins obtained from natural or artificial 
sources. 
These and objects of the present invention are set forth in, 
or will become obvious from. the description of the pre- 
ferred embodiments provided hereinbelow. 
BFUEF DESCFUFHON OF THE! DRAWING 
FIGURES: 
FIG. 1 is a stereo view illustrating the overall topology of 
human serum albumin. 
FIG. 2 is a representation of the sequence homology of the 
amino acid sequences of a variety of the serum albumins 
including from top to bottom, human serum albumin (SEQ 
ID N0:3). bovine serum albumin (SEQ ID NO:4). equine 
serum albumin (SEQ ID N0:5). ovine serum albumin (SEQ 
ID NO:6). rat serum albumin (SEQ ID NO:7). fiog serum 
albumin (SEQ ID NO%). and salmon serum albumin (SEQ 
ID NO:9). 
DERAILED DESCRIPTION OF THE 
PREFERRED EMBODIMENTS: 
In accordance with the present invention, the character- 
istic binding locations of the serum albumin family of 
proteins were determined crystallographically at 3.1 Ang- 
stroms using a wild-type human serum albumin (HSA) and 
at 2.8 Angstroms for a recombinant form of HSA expressed 
in yeast (rHSA). A complete description of the structural 
determination of a serum albumin protein through crystal- 
lographic means is set forth in Nature. Vol. 358:209 (July 
1992). incorporated herein by reference. These crystallo- 
graphic studies confirmed that the topology of serum albu- 
mins such as human serum albumin is created by a repeating 
series of six helical subdomains. known as IA. IB, IIA. IIB. 
EL4 and JIIB. These six subdomains assemble to form a 
heart-shaped molecule. as had previously been determined 
in the stereo view illustration as observed in FIG. 1. 
However, the previous determinations of the serum albumin 
structure gave little insight into its binding locations. and it 
was previously thought that a number of the helical subdo- 
mains were involved in albumin binding. 
The detailed crystallography studies indicated that con- 














regions were located specifically in subdomain IIA and 
subdomain EL4. The binding cavity in region mA appears 
to be the most active and accommodating on the human 
serum albumin, and many ligands have been found to 
preferentially bind in this region. such as digitoxin, ibupro- 
fen and tryptophan. Other ligand binding afiinities have been 
tested, and relative binding locations have now been deter- 
mined crystallographically for several ligands at low 
resolution. as set forth below in Table 1. These tests showed 
that aspirin and iodinated aspirin analogues show nearly 
equal distributions between binding sites IIAand IILA, while 
the composition known as Warfarin appears to occupy a 
single site in IIA. Further. the amino acid residues that have 
previously been thought to be involved in the binding 
process. Trp 214. Lys 199 and Tyr 411, are all located 
strategically in the IIA or IIL4 regions. 
TABLE I 
L i g d  binding locations to HSA 
ObsmrCd 










































Ligand-HSA complexes a d  X-ray diffraction data wen obtaind in a mamKf 
as previously described inTable 1. The observed lccatioos =fer to tbe primary 
binding sites. 
D, Resolution or d-swing in A. 
N, Number of paired miqw reflections with F > 50. 
LF, - F&Fp 
AZT, 3’-Azido-Ydmxythymidine. 
IS, 5-iodosaiicylic acid. 
DIS, 3J-Duodosalicylic acid. 
TIB, 2,3,5-Triiodoberaoic acid 
The structural determination of the binding regions of the 
serum albumin family of proteins shows that the amino acid 
sequences appear to be homologous along the various serum 
albumins. which is evidenced in FIG. 2 wherein the amino 
acid sequences of human, bovine. equine, ovine, rat. frog 
and salmon albumins are compared The crystallographic 
studies conducted in order to locate and identify the albumin 
protein binding sites appear to show that the IIA subdomain 
is one of the key binding sites of the albumin protein, and 
th is  region corresponds to an amino acid sequence beginning 
at approximately amino acid number 190 of the albumin 
protein and extending to about amino acid number 300. In 
one specific embodiment. the sequence for the binding 
region IIA as determined in bovine serum albumin is set 
forth at in  SEQ ID NO: 1. and this sequence runs fiom amino 
acid number 190 through amino acid number 298 on bovine 
serum albumin. 
The crystallographic studies carried out by the inventor 
also revealed that the IUA subdomain was another key 
binding site on the albumin family of proteins. and this 
binding subdomain corresponds to a sequence of amino 
acids which starts at about amino acid number 375 and 
extends to about amino acid number 495. In  another specific 
embodiment. binding region IIIA has an amino acid 
sequence as set forth in SEQ ID N0:2. and this sequence 
appears to run from amino acid 378 through 494. In accor- 
dance with the present invention, a protein fragment con- 
5.780.594 
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taining at least one of the binding regions IIA or IDA amino acid residues 390.391,410.411.4~Z, 437.450.453 
discussed above can be prepared which will have the same and 485 of the IIL4 region. It is thus contemplated that any 
or similar biological activity as a whole natural serum protein fragment that is constructed to contain at least the 
albumin. key residues of either or both of the subdomains ITA and mA 
In addition to the specific binding regions IIA or IDA as set forth above will also exhibit binding properties 
discussed above. there also appears to be an additional equivalent or similar to that of the whole albumin molecules. 
fusion product of subdomains IIA and IIIA that also acts to ~n summary. the present invention allows for the produc- 
give serum albumin some of its binding properties. This tion of protein fragments containing specific binding sites of 
fusion Product appears to be a fragment that includes not the albumin proteins which can be generated by conven- 
only binding regions as tional recombinant DNA techniques and which have the 
well. A protein fragment in accordance with the present Same or similar binding properties as the natural Serum 
invention can thus also be constructed which contains the albumins. It is thus contemplated that these protein frag- 
region including and m+ and this region COZTe- ments can be prepared efficiently and economically in large 
SPOndS roughly to an amino acid sequence extending from l5 quantities so as to substituted for the natural form of the 
about amino acid 190 to about amino acid 495 on a serum albumins in a variety of applications without any loss of 
albumin f d y  protein. Further, it is possible that Such a binding strength. AS set forth herein. the t a m  “protein 
fragment would be even more biologically active and more fragment” is well understood the those skilled in the art and 
likely to Preserve all Of the original binding Peculiarities 2o generally refers to those polypeptides comprising an amino 
associated with the albumin family Of proteins since there acid sequence that only constitutes a podion of a whole 
are sometimes measurable allosteric effects between the protein molecule. 
subdomains. These protein fragments. when constructed artificially 
The isolation of any of the specific albumin family using state-of-the-art recombinant means, will not only have 
binding regions discussed above is advantageous in that not 25 the same OT similar biological activity of the natural whole 
only can biologically active serums be produced from is* albumin proteins, but will also be safer that the natural form 
lates of these binding fragments from the natural albumins. of the albumins since they will not cany many of the other 
but recombinant methods can be used as well to construct viral or other pathogenic contaminants that are found in the 
protein fragments containing only these specific binding 3o natural products. As set forth herein. the term “biological 
regions. In fact. the present invention is particularly advan- activity” is well understood to one skilled in the art and is 
tageous because the protein fragments of the invention can used generally to refer to the ability of a particular molecule. 
be prepared artificially using conventional recombinant such as a whole protein or a particularly active fragment 
DNA techniques. and these fragments will be safer. more from a whole protein. to successfully carry out any of a 
stable and more effective than the natural serums in a variety 35 number of biological or biochemical functions. 
of applications, including column chromatography. When preparing fragments containing the specific binding 
biosensors. crystallographic of solution drug binding regions of the present invention. it will be well understood 
experimentation. and a wide range of medical and biochemi- by those skilled in the that a number of alternate 
cal procedures and experimentation. Thus. although isolates 4o sequences can 
of the albumin proteins can be produced according to the manner from h e  binding regions as discuss& above, yet 
present invention With one or more Of the actual binding which are considered within the scope of the invention. For 
regions obtained from natural sources. it is preferred that example, these alternate embodiments include those frag- 
conventional recombinant techniques be used to manufac- merits 01 sequences which have slight variations as to 
ture the protein fragments containing Or COlTeSpOnding to at 45 specific amino ad&, such as those which include an ad&- 
least one Of the binding regions discussed above. and these tion or deletion of a particular amino acid possibly at the 
artificial fragments can be recovered and/or purified SO as to lading or trailing end of the fragment, which maintain the 
Useful in aPPkatiOnS where natural serum albumin binding properties of the albumin f d y  of proteins in the 
would be used. 5o manner set forth above. Additionally, those sequences which 
In another aspect of the present invention, it has also been contain certain changes in specific amino acids which may 
discovered that key invariant residues that are involved in enhance or decrease the binding affinity of various 
the ligand binding subdomains and which are conserved in compounds. or reduce the likelihood of producing an anti- 
most or all the known albumins. and these key residues genic response, will also be within the scope of the invention 
would thus appear to be primarily responsible for the 55 as would be obvious to one of ordinary skill in  the art. 
binding properties attributed to these regions. Based on an Finally, as set forth above. it is contemplated that because 
examination of the sequence homology as observed in F’IG. the subdomain regions of the multigene family of albumin 
2. and based on other studies involving the crystallographic proteins appear to be the same or similar. the biologically 
patterns of the albumin proteins, it appears that there are active protein fragments of the present invention can be 
certain key residues that are conserved between all of the constructed from specific binding regions of any of the 
determined albumin sequences and that fit precisely in the proteins of the serum albumin family. such as the Gc and 
binding regions IIA and lIIA discussed above. In particular. AFPproteins discussed above. AU of these embodiments are 
these key invariant or conserved residues appear to be at deemed to be covered within the scope of the present 
amino acid residues 257 and 260 of the IIA region. and at invention which is set forth in the claims appended hereto. 
and m. but ~bdomain 






( 1 ) G E N E R A L m O N :  
( i i i )NUMBEROFSEQUENCES:9 
( 2 ) INFORMpnON FOR SEQ ID N0.1: 
( I ) SEQUENCE CHAIucTwSTlCS:  
( A  )LENOM: 109mnkoadds 
( 9  )TYPE:muhoacid 
( C )STRANDEDNESS: sin& 
( D ) TOPOLOGY: linear 
( i i )MOLECULETYPEp&n 
( v ) FRAGMENTTYPE: in tCrd  
( x i ) SEQUENCE DESCRIPTION SEQ ID N0:I: 
A l a  S e r  S e r  A l a  A r g  G l n  A r g  L e u  A r g  C y s  A l a  S e r  I l e  G l n  L y s  P b e  
I 5 1 0  15 
G l y  G l u  A r g  A l a  L e u  L y s  A l a  T r p  S e r  V a l  A l a  A r g  L e u  S e r  G l n  L y s  
2 0  2 5  3 0  
P h s  P r o  L y s  A l a  G l u  P h e  V a l  G l u  V a l  T h r  L y s  L c u  V a l  T h r  A s p  L e u  
3 5  4 0  4 5  
T b r  L y s  V a l  H i s  L y s  G l u  C y s  C y s  H i s  G l y  A s p  L e u  L e u  G l u  C y s  A l a  
5 0  5 5  6 0  
A s p  A s p  A r g  A l a  A s p  L e u  A l a  L y s  T y r  I l e  C y s  A s p  A s n  G l n  A s p  T h r  
6 5  7 0  7 5  8 0  
I l e  S c r  S e r  L y s  L e u  L y s  G l u  C y s  C y s  A s p  L y s  P r o  L e u  L e u  G l u  L y s  
8 5  9 0  9 5  
S c r  H i s  C y s  I l e  A l a  G l u  V a l  G l u  L y s  A s p  A l a  I I e  P r o  
1 0 0  1 0 5  
( 2 ) INFOIUMATION FOR SEQ ID m2 
( i )SEQuENCECHARACTE?RtsIIcs: 
( A )LENGTH: 117amimaddS 
( B  )TypE:amioOacid 
( D  )Topou)GY:linca 
( i i )MOLECULETYPE:p& 
( i i i )HYRXHETCAL:NO 
( i v ) ANTlSENSE NO 
( v ) FRAGMENT TWE: N - m m b l  
( x i ) SEQUENCE DEscRIpI1ON SEQ ID N O 2  
H i s  L e u  V a l  A s p  G l u  P r o  G l o  A s n  L e u  I l c  L y s  G l n  A s n  C y s  A s p  G I n  
1 5 1 0  I 5  
P b e  G l u  L y s  L e u  G l y  G l u  T y r  G l y  P h e  G l o  A s n  A l a  L e u  1 1 s  V a l  A i g  
2 0  2 5  3 0  
T y r  T b r  A r g  L y s  V a l  P r o  G l o  V a l  S s r  T b r  P r o  T b r  L e u  V a l  G l u  V a l  
3 5  4 0  4 5  
S c r  A r g  S e r  L e u  G l y  L y s  V a l  G l y  T h r  A r g  C y s  C y s  T h r  L y s  P r o  G I 0  
5 0  5 5  6 0  
S e r  G l u  A r g  M e t  P r o  C y s  T h r  G I u  A s p  T y r  L e u  S s r  L e u  I l e  L e u  A s n  
6 5  7 0  7 5  8 0  
A r g  L e u  C y s  V a l  L e u  His G l u  L y s  T h r  P r o  V a l  S e r  G l u  L y s  V a l  T b r  
8 5  9 0  9 5  




I O 0  1 0 5  1 1 0  
L e u  T h r  P r o  A s p  G l u  
1 1 5  
( 2 )INFORMATION FOR SEQ ID NOJ: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGm 585 mim s i &  
( B )TYPE: aminoacid 
( D ) TOFOLOGY: linear 
( i i )MOLECULETYPEpotcin 
( i i i )HYPOTHEI1CAL:NO 
( i v )ANll-SENSE:NO 
( v ) FRAGMENT TYPE: N-taminal 
( x i ) SEQUENCE DESCRIpnON. SEQ ID N0:3: 
A s p  A l a  His L y s  S e r  G l u  V a l  A l a  His A r g  P h e  L y s  A s p  L e u  G l y  G l u  
I 5 I O  1 5  
G l u  A s n  P h e  L y s  A l a  L e u  V a l  L e u  I l e  A l a  P h e  A l a  G i n  T y r  L e u  G l u  
2 0  2 5  3 0  
G l n  C y s  P r o  P h e  G l u  A s p  His V a l  L y s  L e u  V a l  A s n  G l u  V a l  T h r  G l u  
3 5  4 0  4 5  
P h e  A l a  L y s  T h r  C y s  V a l  A l a  A s p  G l u  S c r  A l a  G l u  A s n  C y s  A s p  L y s  
5 0  5 5  6 0  
S e r  L e u  His T h r  L e u  P h c  G l y  A s p  L y s  L e u  C y s  T b r  V a l  A l a  T b r  L e u  
6 5  7 0  7 s  8 0  
A r g  G l u  T b r  T y r  G l y  G l u  M e t  A l a  A s p  C y s  C y s  A l a  L y s  G l n  G l u  P r o  
8 5  9 0  9 5  
G l u  A r g  A s n  G l u  C y s  P h c  L e u  G l n  His L y s  A s p  A s p  A s n  P r o  A s n  L e u  
I O 0  1 0 5  1 I O  
P r o  A r g  L e u  V a l  A r g  P r o  G l u  V a l  A s p  V a l  M e t  C y s  T h r  A l a  P h c  His 
1 1 5  1 2 0  1 2 5  
A s p  A s n  G l u  G l u  T b r  P h e  L e u  L y s  L y s  T y r  L e u  T y r  C i l u  I l e  A l a  A r g  
1 3 0  1 3 5  1 4 0  
A r g  H i s  P r o  T y r  P b e  T y r  A l a  P r o  G l u  L e u  L e u  P b e  P b e  A l a  L y s  A r g  
1 4 5  1 5 0  1 5 5  1 6 0  
T y r  L y s  A l a  A l a  P h e  T h r  G l u  C y s  C y s  G l n  A l a  A l a  A s p  L y s  A l a  A l a  
1 6 5  1 7 0  1 7 5  
C y s  L e u  L e u  P r o  L y s  L e u  A s p  G l u  L e u  A r g  A s p  O l u  G l y  L y s  A l a  S e r  
1 8 0  1 8 5  I 9 0  
S e r  A l a  L y s  G l n  A r g  L e u  L y s  C y s  A l a  S e r  L e u  G l u  L y s  P h e  G l y  G l u  
1 9 5  2 0 0  2 0 5  
A r g  A l a  P b e  L y s  A l a  T r p  A l a  V a l  A l a  A r g  L e u  S e r  G l n  A r g  P b e  P r o  
2 1 0  2 1 5  2 2 0  
L y s  A l a  G l u  P b e  A l a  G l u  V a l  S c r  L y s  L e u  V a l  T h r  A s p  L e u  T h r  L y s  
2 2 5  2 3 0  2 3  5 2 4 0  
V a l  His T b r  G l u  C y s  C y s  H i s  G l y  A s p  L e u  L e u  G l u  C y s  A l a  A s p  A s p  
2 4 5  2 5 0  2 5 5  
A r g  A l a  A s p  L e u  A l a  L y s  T y r  I l e  C y s  G l u  A s n  G l n  A s p  S e r  I l e  S e r  
2 6 0  2 6 5  2 7 0  
S c r  L y n  L e u  L y s  G l u  C y s  C y s  O l u  L y s  P r o  L e u  L e u  G l u  L y a  S c r  H i s  
2 7 5  2 8 0  2 8 5  
C y s  I l e  A l a  G I u  V a l  G l u  A s n  A s p  G l u  M e t  P r o  A l a  A s p  L e u  P r o  S e r  




~~ ~ ~~~ ~ ~~ 
L e u  A l a  A l a  A s p  P h e  V a l  G l u  S c r  L y s  A s p  V a l  C y s  L y s  A s n  T y r  A l a  
3 0 5  3 1 0  3 1 5  3 2 0  
G l u  A l a  L y s  A s p  V a l  P h c  L e u  G l y  M e t  P h e  L e u  T y r  G l u  T y r  A l a  A r g  
3 2 5  3 3 0  3 3 5  
A r g  His P r o  A s p  T y r  S c r  V a l  V a l  L e u  L e u  L e u  A r g  L e u  A l a  L y s  T h r  
3 4 0  3 4 5  3 5 0  
T y r  G l u  T h r  T b r  L e u  G l u  L y s  C y s  C y s  A l a  A l a  His A s p  P r o  His G l u  
3 5 5  3 6 0  3 6 5  
C y s  T y r  A l a  L y s  V a l  P h c  A s p  G l u  P b c  L y s  P r o  L e u  V a l  G l u  G l u  P r o  
3 7 0  3 7 5  3 8 0  
G l n  A s o  L e u  I l e  L y s  G l n  A s n  C y s  G l u  L e u  P h e  L y s  G l n  L e u  G l y  G l u  
3 8 5  3 9 0  3 9 5  4 0 0  
T y r  L y s  P h e  G l n  A s n  A l a  L e u  L e u  V a l  A r g  T y r  T h r  L y s  L y s  V a l  P r o  
4 0 5  4 1 0  4 1 5  
G l n  V a l  S e r  T b r  P r o  T h r  L e u  V a l  G l u  V a l  S e r  A r g  A s n  L e u  G l y  L y s  
4 2 0  4 2 5  4 3 0  
V a l  G l y  S c r  L y s  C y s  C y s  L y s  His P r o  G l u  A l a  L y s  A r g  M e t  P r o  C y s  
4 3  5 4 4 0  4 4 5  
A l a  G l u  A s p  T y r  L e u  S c r  V a l  V a l  L e u  A s n  G l n  L e u  C y s  V a l  L e u  His 
4 5 0  4 5 5  4 6 0  
G l u  L y s  T h r  P r o  V a l  S e r  A s p  A r g  V a l  T h r  L y s  C y s  C y s  T h r  G l u  S e r  
4 6  5 4 7 0  4 7 5  4 8 0  
L e u  V a l  A s n  A r g  A r g  P r o  C y s  P h e  S e r  A l a  L e u  G l u  V a l  A s p  G I u  T h r  
4 8 5  4 9 0  4 9 5  
T y r  V a l  P r o  L y s  G l u  P h e  A s n  A l a  G l u  T h r  P h c  T h r  P h e  His A l a  A s p  
5 0 0  5 0 5  5 1 0  
I l e  C y s  T h r  L e u  S e r  G I "  L y s  G l u  A r g  G l n  I l c  L y s  L y s  G I n  T h r  A l a  
5 1 5  5 2 0  5 2 5  
L e u  V a l  G l u  L e u  V a l  L y s  His L y s  P r o  L y s  A l a  T h r  L y s  G l u  G l n  L e u  
5 3 0  5 3 5  5 4 0  
L y s  A l a  V a l  M e t  A s p  A s p  P b e  A l a  A l a  P h e  V a l  G l u  L y s  C y s  C y s  L y s  
5 4 5  5 5 0  5 5 5  5 6 0  
A l a  A s p  A s p  L y s  G l u  T h r  C y s  P h e  A l a  G l u  G l u  G l y  L y s  L y s  L e u  V a l  
5 6 5  5 7 0  5 7 5  
A l a  A l a  S e r  G l n  A l a  A l a  L e u  G l y  L e u  
5 8 0  5 8 5  
( 2 ) INFORMHION FOR SEQ ID N04: 
( i ) SEQUENCECHARACTERISIICS: 
( A  )LENQlli:583sninOacidp 
( 8  )lYF?Esndnoa~id 
( D )TopoIxMxLnca 
( i i )MOLECULETYPE:pacin 
( i i i ) m C A L : N O  
( i v ) ANn-SENSE: NO 
( v  )FRAGMENTTYPE:N-olmina 
( x i ) SEQUENCE DEscRIpI1ON SEQ ID NO4 
A s p  T b r  His L y s  S s r  G l u  I l c  A l a  His A r g  P h e  L y s  A s p  L e u  G l y  G l u  
1 5 10 1 5  
G I u  His P h e  L y s  G l y  L e u  V a l  L e u  I l e  A l a  P h e  S e r  G l n  T y r  L c u  G l n  
2 0  2 5  3 0  
G l n  C y s  P r o  P h c  A s p  G l u  His V a l  L y s  L e n  V a l  A s n  G l u  L e u  T h r  G l u  




P h e  A l a  L y s  T h r  C y s  V a l  A l a  A s p  G l u  S c r  H i s  A l a  G l y  C y s  G l u  L y s  
5 0  5 5  6 0  
S c r  L e u  H I S  T h r  L e u  P h e  G l y  A s p  G l u  L e u  C y s  L y s  V a l  A l a  S c r  L e u  
6 5  70 7 5  8 0  
A r g  G l u  T h r  T y r  G l y  A s p  M e t  A l a  A s p  C y s  C y s  F L U  L y s  G l n  G l u  P r o  
8 5  9 0  9 5  
G l u  A r g  A s n  G l u  C y s  P h e  L e u  S c r  H i s  L y n  A s p  A s p  S c r  P r o  A s p  L e u  
1 0 0  1 0 5  1 1 0  
P r o  L y s  L e u  L y s  P r o  A s p  P r o  A s n  T h r  L e u  C y s  A s p  G l u  P h e  L y s  A l a  
I 1 5  1 2 0  1 2 5  
A s p  G l u  L y s  L y s  P h e  T r p  G l y  L y s  T y r  L e u  T y r  G l u  I l c  A l a  A r g  A r g  
1 3 0  1 3 5  I 4 0  
H i s  P r o  T y r  P h c  T y r  A l a  P r o  G l u  L e u  L e u  T y r  T y r  A l a  A s n  L y s  T y r  
1 4 5  1 5 0  1 5 5  1 6 0  
A s n  G l y  V a l  P h c  G l n  G l u  C y s  C y s  G l n  A l a  G l u  A s p  L y s  G l y  A l a  C y s  
1 6 5  1 7 0  1 7 5  
L e u  L e u  P r o  L y s  I l c  G l u  T h r  M e t  A r g  G l u  L y s  V a l  L e u  A l a  S c r  S c r  
1 8 0  1 8 5  1 9 0  
A l a  A r g  G l n  A r g  L e u  A r g  C y s  A l a  S c r  I l e  G l n  L y s  P b e  G l y  G l u  A r g  
1 9 5  2 0 0  2 0 5  
A l a  L e u  L y s  A l a  T r p  S c r  V a l  A l a  A r g  L e u  S e r  G l n  L y s  P h e  P r o  L y s  
2 1 0  2 1 5  2 2 0  
A l a  G I u  P h c  V a l  G l u  V a l  T h r  L y s  L e u  V a l  T h r  A s p  L e u  T h r  L y s  V a l  
2 2 5  2 3 0  2 3 5  2 4 0  
H i s  L y s  G l u  C y s  C y s  H i s  G l y  A s p  L e u  L e u  G l u  C y s  A l a  A s p  A s p  A r g  
2 4 5  2 5 0  2 5 5  
A l a  A s p  L e u  A l a  L y s  T y r  l i e  C y s  A s p  A s n  G l n  A s p  T h r  1 1 s  S c r  S e i  
2 6 0  2 6 5  2 7 0  
L y s  L e u  L y s  G l u  C y s  C y s  A s p  L y s  P r o  L e u  L e u  G l u  L y s  S c r  H i s  C y s  
2 7 5  2 8 0  2 8 5  
I l c  A l a  G l u  V a l  G l u  L y s  A s p  A l a  I I c  P r o  G l u  A s n  L e u  P r o  P r o  L e u  
2 9 0  2 9 5  3 0 0  
T h r  A l a  A s p  P h c  A l a  G l u  A s p  L y s  A s p  V a l  C y s  L y s  A s n  T y r  G l n  G l u  
3 0 5  3 1 0  3 1 5  3 2 0  
A l a  L y s  A s p  A l a  P h c  L e u  G l y  S c r  P h c  L e u  T y r  G l u  T y r  S c r  A r g  A r g  
3 2 5  3 3 0  3 3 5  
H i s  P r o  G l u  T y r  A l a  V a l  S e r  V a l  L e u  L e u  A r g  L e u  A l a  L y s  G l u  T y r  
3 4 0  3 4 5  3 5 0  
G l u  A l a  T h r  L e u  G l u  G l u  C y s  C y s  A l a  L y s  A s p  A s p  P r o  H i s  A l a  C y s  
3 5 5  3 6 0  3 6 5  
T y r  S e r  T b r  V a l  P h c  A s p  L y s  L e u  L y s  His L e u  V a l  A s p  G l u  P r o  G l n  
3 7 0  3 7 5  3 8 0  
A s n  L e u  1 1 s  L y s  G l n  A s n  C y s  A s p  G l n  P h e  G l u  L y s  L e u  G l y  G l u  T y r  
3 8 5  3 9 0  3 9 5  4 0 0  
G l y  P h c  Gln A s n  A l a  L e u  I l e  V a l  A r g  T y r  T h r  A r g  L y s  V a l  P r o  G l n  
4 0 5  4 1 0  4 1 5  
V a l  S e r  T b r  P r o  T h r  L e u  V a l  G l u  V a l  S e r  A r g  S c r  L e u  G l y  L y s  V a l  
4 2 0  4 2 5  4 3 0  
G l y  T h r  A r g  C y s  C y s  T h r  L y s  P r o  G l u  S c r  G l u  A r g  M e t  P r o  C y s  T h r  
4 3 5  4 4 0  4 4 5  
G l u  A s p  T y r  L e u  S e r  L e u  1 1 s  L e u  A s n  A r g  L e u  C y s  V a l  L e u  His G l u  
4 5 0  4 5  5 4 6 0  




4 6 5  4 7 0  4 7 5  4 8 0  
V a l  A s n  A r g  A r g  P r o  C y s  P b e  S e r  A l a  L e u  T h r  P r o  A s p  G I u  T b r  T y r  
4 8 5  4 9 0  4 9 5  
V a l  P r o  L y s  A l a  P h e  A s p  G l u  L y s  L e u  P b c  T h r  P b c  H i s  A l a  A s p  l l c  
5 0 0  5 0 5  5 1 0  
C y s  T b t  L e u  P r o  A s p  T b r  G l u  L y s  Gln I l e  L y s  L y s  G l n  T b r  A l a  L e u  
5 1 5  5 2 0  5 2 5  
V a l  G l u  L e u  L e u  L y s  His L y s  P r o  L y s  A l a  T h r  G l u  G l u  G l n  L e u  L y s  
5 3 0  5 3 5  5 4 0  
T b r  V a l  M e r  G l u  A s n  P b c  V a l  A l a  P h c  V a l  A s p  L y s  C y s  C y s  A l a  A l a  
5 4 5  5 5 0  5 5 5  5 6 0  
A s p  A s p  L y s  G l u  A l a  C y s  P b c  A l a  V a l  G l u  G l y  P r o  L y s  L e u  V a l  V a l  
5 6 5  5 7 0  5 7 5  
S c r  T b r  G l n  T b r  A l a  L e u  A l a  
5 8 0  
( 2 ) INFORMATION FOR SEQ ID N05: 
( i )~UENCZCHARACTEIUSTlCS: 
( A  )LENOTH:583arirmadds 
( B  )TypE.&oacid 
( D )TOPOLOGY: linca 
( i i )MaECULETYPE:pM& 
( i i i ) m C A L : N O  
( i v ) M S W S E :  NO 
( v  )FRAGIbW&TTYPE:N-urminal 
( x i ) SEQUENCE DESCRIPTION: SEQ ID NOS: 
A s p  T b r  H i s  L y s  S e r  G l u  l l e  A l a  H i s  A r g  P b c  A s n  A s p  L e u  G l y  Glu 
1 5 1 0  I 5  
L y s  His P b c  L y s  G l y  L e u  V a l  L e u  V a l  A l a  P h e  S c r  G l n  T y r  L e u  G l n  
2 0  25 3 0  
G l n  C y s  P r o  P b e  G l u  A s p  H i s  V a l  L y s  L e u  V a l  A s n  Glu V a l  T h r  G l u  
3 5  40 4 5  
P b e  A l a  L y s  L y s  C y s  A l a  A l a  A s p  G l u  S c r  A l a  G l u  A s n  C y s  A s p  L y s  
5 0  5 5  6 0  
S e r  L e u  H i s  T b r  L e u  P b e  G l y  A s p  L y s  L e u  C y 9  T h r  V a l  A l a  T b r  L e u  
6 5  7 0  7 5  8 0  
A r g  A l a  T h r  T y r  G l y  G l u  L e u  A l a  A s p  C y s  C y s  G I u  L y s  G l a  G l u  P r o  
8 5  9 0  9 5  
G l u  A r g  A s n  G l u  C y s  P b c  L e u  T b r  H i s  L y s  A s p  A s p  H i s  P r o  A s n  L e u  
1 0 0  1 0 5  1 1 0  
P r o  L y s  L e u  L y s  P r o  G l u  P r o  A s p  A l a  G l n  C y s  A l a  A l a  P h c  G l n  G l u  
1 1 5  1 2 0  1 2 5  
A s p  P r o  A s p  L y s  P h e  L e u  G l y  L y s  T y r  L e u  T y r  G l u  V a l  A l a  A r g  A r g  
1 3 0  1 3 5  140 
H i s  P r o  T y r  P h c  T y r  G l y  P r o  G l u  L e u  L e u  P h e  H i s  A l a  G l u  G l u  T y r  
1 4 5  1 5 0  1 5 5  160 
L y s  A l a  A s p  P h c  T h r  G l u  C y s  C y s  P r o  A l a  A s p  A s p  L y s  L e u  A l a  C y s  
1 6 5  I 7 0  1 7 5  
L e u  1 I c  P r o  L y s  L e u  A s p  A l a  L e u  L y r  G l u  A r g  I l e  L e u  L e u  S e r  S e i  
1 8 0  1 8 5  1 9 0  
A l a  L y s  G l u  A r g  L e u  L y s  C y s  S e r  S e r  P b e  G l n  A s n  P h c  O l y  G l u  A r g  




A l a  V a l  L y s  A l a  T r p  S c r  V a l  A l a  A r g  L c u  S c r  G l n  L y s  P h c  P r o  L y s  
2 1 0  2 1 5  2 2 0  
A l a  A s p  P h c  A l a  G I u  V a l  S c r  L y s  I l c  V a l  T h r  A s p  L c u  T h r  L y s  V a l  
2 2 5  2 3 0  2 3 5  2 4 0  
His L y s  G l u  C y s  C y s  His G l y  A s p  L c u  L e u  G l u  C y s  A l a  A s p  A s p  A r g  
2 4 5  2 5 0  2 5 5  
A l a  A s p  L c u  A l a  L y s  T y r  I l c  C y s  G l u  His G l n  A s p  S c r  1 1 s  S e r  G l y  
2 6 0  2 6 5  2 7 0  
L y s  L c u  L y s  A l a  C y s  C y s  A s p  L y s  P r o  L C U  L e u  G l n  L y s  S e r  His C y s  
2 7 5  2 8 0  2 8 5  
I l e  A l a  G l u  V a l  L y s  G l u  A s p  A s p  L c u  P r o  S e r  A s p  I l c  P r o  A l a  L C U  
2 9 0  2 9 5  3 0 0  
A l a  A l a  A s p  P h e  A l a  G l u  A s p  L y s  G l u  I l e  C y s  L y s  His T y r  L y s  A s p  
3 0 5  3 1 0  3 1 5  3 2 0  
A l a  L y s  A s p  V a l  P h c  L e u  G l y  T h r  P h c  L c u  T y r  G l u  T y r  S c r  A r g  A r g  
3 2 5  3 3 0  3 3 5  
His P r o  A s p  T y r  S c r  V a l  S e r  L e u  L c u  L c u  A r g  I l e  A l a  L y s  T h r  T y r  
3 4 0  3 4 5  3 5 0  
G l u  A l a  T h r  L e u  G l u  L y s  C y s  C y s  A l a  G l u  A l a  A s p  P r o  P r o  A l a  C y s  
3 5 5  3 6 0  3 6 5  
T y r  A r g  T h r  V a l  P b c  A s p  G l n  P h c  T h r  P r o  L c u  V a l  G l u  G l u  P r o  L y s  
3 7 0  3 7 5  3 8 0  
S e r  L C U  V a l  L y s  L y s  A s n  C y r  A s p  L c u  P h c  G l u  G l u  V a l  G l y  G l u  T y r  
3 8 5  3 9 0  3 9 5  4 0 0  
A s p  P h c  G l n  A s n  A l a  L e u  I l c  V a l  A r g  T y r  T h r  L y s  L y s  A l a  P r o  G l n  
4 0 5  4 1 0  4 1 5  
V a l  S c r  T b r  P r o  T h r  L c u  V a l  G l u  I l e  G l y  A r g  T h r  L e u  G l y  L y s  V a l  
4 2 0  4 2 5  4 3 0  
G l y  S c r  A r g  C y s  C y s  L y s  L e u  P r o  G l u  S c r  G l u  A r g  L e u  P r o  C y s  S c r  
4 3 5  4 4 0  4 4 5  
G l u  A s n  His L e u  A l a  L e u  A l a  L c u  A s n  A r g  L c u  C y s  V a l  L e u  His G l u  
4 5 0  4 5 5  4 6 0  
L y s  T h r  P r o  V a l  S e r  G l u  L y s  l l c  T b r  L y s  C y s  C y s  T h r  A s p  S c r  L e u  
4 6  5 4 7 0  4 7 5  4 8 0  
A l a  G l u  A r g  A r a  P r o  C y s  P b c  S c r  A l a  L e u  G l u  L c u  A s p  O l u  G l y  T y r  
4 8 5  4 9 0  4 9 5  
P r o  V a l  L y s  G l u  P h c  L y s  A l a  G l u  T b r  P h c  T h r  P b e  H i s  A l a  A s p  I I c  
5 0 0  5 0 5  5 1 0  
C y s  T b r  L C U  P r o  G l u  A s p  G l u  L y s  Gln I l e  L y s  L y s  G l n  S c r  A l a  L e u  
5 1 5  5 2 0  5 2 5  
A l a  G l u  L e u  V a l  L y s  His L y s  P r o  L y s  A l a  T h r  L y s  G l u  G l n  L c u  L y s  
5 3 0  5 3 5  5 4 0  
T h r  V a l  L e u  G l y  A s n  P b c  S c r  A l a  P b e  V a l  A l a  L y s  C y s  C y s  G l y  A r g  
5 4 5  5 5 0  5 5 5  5 6 0  
G l u  A s p  L y s  G l u  A l a  C y s  P h e  A l a  G l u  G l u  G l y  P r o  L y s  L e u  V a l  A l a  
5 6 5  5 7 0  5 7 5  
S e r  S c r  G l n  L e u  A l a  L c u  A l a  
5 8 0  
( 2 ) INPDRMATION FOR SeQ ID NO* 
( i ) SEQUENCE CHARACI'ERISTICS: 
(A)LENGTH:583&acids 
( B  )TYPE:aninoecid 
( D ) TomLcx3y: linear 
5.780.594 
-continued 
( i i )MOLE!CULETYF'E:pr& 
( i  i i )HywIHEI1CAL:NO 
( i v ) AN'II-SENSE: NO 
( v ) FRAGhENT TYPE N-tmuid 
( x i ) SEQUENCE DESCRIPIION: SEQ ID N o d :  
A s p  T b r  His L y s  S c r  G l u  I l c  A l a  His A r g  P h c  A s n  A s p  L e u  G l y  G l u  
I 5 10 1 5  
G l u  A s n  P h e  G l n  G l y  L e u  V a l  L e u  I l c  A l a  P h c  S e r  G l n  T y r  L e u  G l n  
2 0  2 5  3 0  
G l n  C y s  P r o  P b c  A s p  G l u  His V a l  L y s  L e u  V a l  L y s  G l u  L e u  T h r  G l u  
3 5  4 0  4 5  
P h e  A l a  L y s  T b r  C y s  V a l  A l a  A s p  G l u  S e r  His A l a  G l y  C y s  A s p  L y s  
5 0  5 5  6 0  
S c r  L e u  His T h r  L e u  P b c  G l y  A s p  G l u  L e u  C y s  L y s  V a l  A l a  T h r  L e u  
6 5  7 0  7 5  8 0  
A r g  G l u  T h r  T y r  G l y  A s p  M e t  A l a  A s p  C y s  C y s  G l u  L y s  G l n  G l u  P r o  
8 5  9 0  9 5  
G l u  A r g  A s n  G l u  C y s  P h e  L e u  A s n  His L y s  A s p  A s p  S c r  P r o  A s p  L e u  
1 0 0  1 0 5  I 1 0  
P r o  L y s  L e u  L y s  P r o  G l u  P r o  A s p  T h r  L e u  C y s  A l a  G l u  P h c  L y s  A l a  
1 1 5  1 2 0  1 2 5  
A s p  G l u  L y s  L y s  P b c  T r p  G l y  L y s  T y r  L e u  T y r  G l u  V a l  A l a  A r g  A r g  
1 3 0  1 3 5  140 
His P r o  T y r  P h e  T y r  A l a  P r o  G l u  L e u  L e u  T y r  T y r  A l a  A s n  L y s  T y r  
1 4 5  1 5 0  I 5 5  1 6 0  
A s n  G l y  V a l  P h c  G l n  G l u  C y s  C y s  G l n  A l a  G l u  A s p  L y s  G l y  A l a  C y s  
1 6 5  1 7 0  1 7 5  
L e u  L e u  P r o  L y s  I l c  A s p  A l a  M e t  A r g  G l u  L y s  V a l  L e u  A l a  S c r  S e r  
1 8 0  1 8 5  1 9 0  
A l a  A r g  G l n  A r g  L e u  A r g  C y s  A l a  S c r  I I c  G l n  L y s  P h e  G t y  G l u  A r g  
1 9 5  2 0 0  2 0 5  
A l a  L e u  L y s  A l a  T r p  S e r  V a l  A l a  A r g  L e u  S c r  G l n  L y s  P b c  P r o  L y s  
2 1 0  2 1 5  2 2 0  
A l a  A s p  P b e  T h r  A s p  V a l  T b r  L y s  [ l e  V a l  T h r  A s p  L e u  T b r  L y s  V a l  
2 2 5  2 3 0  2 3 5  2 4 0  
His L y s  G l u  C y s  C y s  His G l y  A s p  L e u  L e u  G I u  C y s  A l a  A s p  A s p  A r g  
2 4 5  2 5 0  2 5 5  
A l a  A s p  L e u  A l a  L y s  T y r  1 1 s  C y s  A s p  His G l n  A s p  A l a  L e u  S c r  S e r  
2 6 0  26 5 2 7 0  
L y s  L e u  L y s  G l u  C y s  C y s  A s p  L y s  P r o  V a l  L e u  G l u  L y s  S c r  His C y 6  
2 7 5  2 8 0  2 8 5  
I I c  A l a  O l u  V a l  A s p  L y s  A s p  A l a  V a l  P r o  G l u  A n n  L e u  P r o  P r o  L e u  
2 9 0  2 9 5  3 0 0  
T b r  A l a  A s p  P b e  A l a  G l u  A s p  L y s  G l u  V a l  C y s  L y s  A s n  T y r  G l a  G l u  
3 0 5  3 1 0  3 I 5  3 2 0  
A l a  L y s  A s p  V a l  P h c  L e u  G l y  S c r  P h e  L e u  T y r  G l u  T y r  S e r  A r g  A r g  
3 2 5  3 3 0  3 3 5  
His P r o  G l u  T y r  A l a  V a l  S e r  V a l  L e u  L e u  A r g  L e u  A l a  L y s  G l u  T y r  
3 4 0  3 4 5  3 5 0  
G l u  A l a  T h r  L e u  G l u  A s p  C y s  C y s  A l a  L y s  G l u  A s p  P r o  His A l a  C y s  
3 5 5  3 6 0  3 6 5  





3 7 0  3 7 5  3 8 0  
A s n  L e u  I l e  L y s  L y s  A s n  C y s  G l u  L e u  P b e  G l u  L y s  His G l y  G l u  T y r  
3 8 5  3 9 0  3 9 5  4 0 0  
G l y  P b e  G l n  A s n  A l a  L e u  ! I C  V a l  A r g  T y r  T h r  A r g  L y s  A l a  P r o  G l n  
4 0 5  4 1 0  4 1 5  
V a l  S e r  T h r  P r o  T b r  L e u  V a l  G l u  I l e  S e r  A r g  S c r  L e u  G l y  L y s  V a l  
4 2 0  4 2 5  4 3 0  
G l y  T h r  L y s  C y s  C y s  A l a  L y s  P r o  G l u  S e r  G l u  A r g  M e t  P r o  C y s  T h r  
4 3 5  4 4 0  4 4 5  
G l u  A s p  T y r  L e u  S e r  L e u  I l c  L e u  A s n  A r g  L e u  C y s  V a l  L e u  His G l u  
4 5 0  4 5 5  4 6 0  
L y s  T b r  P r o  V a l  S e r  G l u  L y s  V a l  T h r  L y s  C y s  C y s  T h r  F l u  S e r  L e u  
4 6 5  4 7 0  4 7  5 4 8 0  
V a l  A s n  A r g  A r g  P r o  C y s  P h e  S e r  A s p  L e u  T h r  L e u  A s p  G l u  T b r  T y r  
4 8 5  4 3 0  4 3 5  
V a l  P r o  L y s  P r o  P h c  A s p  F l u  L y s  P h e  P b c  T h r  P b e  H i s  A l a  A s p  I I c  
5 0 0  5 0 5  5 1 0  
C y s  T h r  L e u  P r o  A s p  T b r  G l u  L y s  G l n  I l c  L y s  L y s  G l n  T h r  A l a  L e u  
5 1 5  5 2 0  5 2 5  
V a l  G l u  L e u  L e u  L y s  His L y s  P r o  L y s  A l a  T h r  A s p  G l u  G l n  L e u  L y s  
5 3 0  5 3 5  5 4 0  
T h r  V a l  M e t  G l u  A s n  P b e  V a l  A l a  P b e  V a l  A s p  L y s  C y s  C y s  A l a  A l a  
5 4 5  5 5 0  5 5 5  5 6 0  
A s p  A s p  L y s  G l u  G l y  C y s  P h e  V a l  L e u  G l u  G l y  P r o  L y s  L e u  V a l  A l a  
5 6 5  5 7 0  s 7 5  
S e r  T b r  G l n  A l a  A l a  L e u  A l a  
5 8 0  
( 2 ) IMORMKTION FOR SEQ ID N O 7  
( i ) SEQUENCE CHARACIZNSTICS: 
( A )LENGTH:584&adds 
( B  )TIpE:irminoaEid 
( D  )TOpoUwjY:~ 
( i i )MOLECULETYPE:prc&n 
( i i i ) -CAL: NO 
( i v ) AN1I-SENSE: N O  
( v ) FRAGMENI T m  N-terminal 
( x i ) SEQUWCE DESCRIPTION SEQ ID N07: 
G l u  A l a  His L y s  S e r  G l u  I l e  A l a  His A r g  P h e  L y s  A s p  L e u  G l y  G l u  
1 5 1 0  I 5  
G l n  His P b e  L y s  G l y  L e u  V a l  L e u  I l e  A l a  P b e  S e r  G l n  T y r  L e u  G l n  
2 0  2 5  3 0  
L y s  C y s  P r o  T y r  G l u  G l u  H i s  I l e  L y s  L e u  V a l  G l n  a l u  V a l  T b r  A s p  
3 5  40 4 5  
P b e  A l a  L y s  T b r  C y s  V a l  A l a  A s p  G l u  A s n  A l a  G l u  A s n  C y s  A s p  L y s  
5 0  5 5  6 0  
S e r  I I e  His T h r  L e u  P b e  G l y  A s p  L y s  L e u  C y s  A l a  1 1 s  P r o  L y s  L e u  
6 5  70 7 5  8 0  
A r g  A s p  A s n  T y r  G l y  G l u  L e u  A l a  A s p  C y s  C y s  A l a  L y a  G l n  G l u  P r o  
8 5  9 0  9 5  
G l u  A r g  A s n  G l u  C y s  P b e  L e u  G l n  H i s  L y s  A s p  A s p  A s n  P r o  A s n  L e u  





P r o  P r o  P h e  G l n  A r g  P r o  G l u  A l a  G l u  A l a  M e t  C y s  T h r  S e r  P h e  G I u  
1 1 5  1 2 0  1 2 5  
G l u  A s n  P r o  T b r  S e r  P b c  L e u  G l y  His T y r  L e u  H i s  G l u  V a l  A l a  A r g  
1 3 0  1 3 5  1 4 0  
A r g  H i s  P r o  T y r  P b e  T y r  A l a  P r o  G l u  L e u  L e u  T y r  T y r  A l a  G l u  L y s  
1 4 5  1 5 0  1 5 5  1 6 0  
T y r  A s n  G l u  V a l  L e u  T b r  G l n  C y s  C y s  T h r  G l u  S e r  A s p  L y s  A l a  A l a  
1 6 5  1 7 0  1 7 5  
C y s  L e u  T h r  P r o  L y s  L e u  A s p  A l a  V a l  L y s  G l u  L y s  A l a  L e u  V a l  A l a  
I 8 0  1 8 5  1 9 0  
A l a  V a l  A r g  G i n  A r g  M e t  L y s  C y s  S e r  S e r  M e t  G l u  A r g  P h c  G l y  G l u  
1 9 5  2 0 0  2 0 5  
A r g  A l a  P h e  L y s  A l a  T r p  A l a  V a l  A l a  A r g  M e r  S e r  G I n  A r g  P b e  P r o  
2 1 0  2 1 5  2 2 0  
A s n  A l a  G t u  P h e  A l a  G l u  I l e  T h r  L y s  L e u  A l a  T b r  A s p  V a l  T h r  L y s  
2 2 5  2 3 0  2 3 5  2 4 0  
I l e  A s n  L y s  G l u  C y s  C y s  H i s  G l y  A s p  L e u  L e u  G l u  C y s  A l a  A s p  A s p  
2 4 5  2 5 0  2 5 5  
A r g  A l a  F l u  L e u  A l a  L y s  T y r  M e t  C y s  G l u  A s n  G l n  A l a  T h r  1 1 s  S c r  
2 6 0  2 6 5  2 7 0  
S e r  L y s  L e u  G l n  A l a  C y s  C y s  A s p  L y s  P r o  V a l  L e u  G l n  L y s  S c r  G l n  
2 7 5  2 8 0  2 8 5  
C y s  L e u  A l a  G l u  T h r  G l u  H I S  A s p  A s n  11.2 P r o  A l a  A s p  L e u  P r o  S e r  
2 9 0  2 9 5  3 0 0  
I l e  A l a  A l a  A s p  P b e  V a l  G l u  A s p  L y s  G l u  V a l  C y s  L y s  A s n  T y r  A l a  
3 0 5  3 1 0  3 1 5  3 2 0  
G l u  A l a  L y s  A s p  V a l  P b e  L e u  G l y  T h r  P b e  L e u  T y r  G l u  T y r  S e r  A r g  
3 2 5  3 3 0  3 3 5  
A r g  H i s  P r o  A s p  T y r  S e r  V a l  S e r  L e u  L e u  L e u  A r g  L e u  A l a  L y s  L y s  
3 4 0  3 4 5  3 5 0  
T y r  G L u  A l a  T b r  L e u  G l u  L y s  C y s  C y s  A l a  G l u  G l y  A s p  P r o  P r o  A l a  
3 5 5  3 6 0  3 6 5  
C y s  T y r  G L y  T b r  V a l  L e u  A l a  G l u  P b e  G l n  P r o  L e u  V a l  G l u  G l u  P r o  
3 7 0  3 7 5  3 8 0  
L y s  A s n  L e u  V a l  L y s  T h r  A s n  C y s  G l u  L e u  T y r  G l u  L y s  L e u  G l y  G l u  
3 8 5  3 9 0  3 9 5  4 0 0  
T y r  G l y  P h e  G l n  A s n  A l a  V a l  L e u  V a l  A r g  T y r  T h r  G l n  L y s  A l a  P r o  
4 0 5  4 1 0  4 1 5  
G I n  V a l  S e r  T h r  P r o  T h r  L e u  V a l  G l u  A l a  A l a  A r g  A s n  L e u  G l y  A r g  
4 2 0  4 2 5  4 3 0  
V a l  G l y  T b r  L y s  C y s  C y s  T h r  L e u  P r o  G l u  A l a  G l n  A r g  L e u  P r o  C y s  
4 3 5  4 4 0  4 4 5  
V a l  G l u  A s p  T y r  L e u  S e r  A l a  I l e  L e u  A s n  A r g  L e u  C y s  V a l  L e u  H i s  
4 5 0  4 5  5 4 6 0  
G l u  L y s  T h r  P r o  V a l  S c r  G l u  L y s  V a l  T h r  L y s  C y s  C y s  S e r  G l y  S e r  
4 6 5  4 7 0  4 7 5  4 8 0  
L e u  V a l  G l u  A r g  A r g  P r o  C y s  P h e  S e r  A l a  L e u  T h r  V a l  A s p  G f u  T h r  
4 8 5  4 9 0  4 9 5  
T y r  V a l  P r o  L y s  G l u  P b e  L y s  A l a  G i u  T h r  P b e  T h r  P h e  H I S  S e r  A s p  
5 0 0  5 0 5  5 1 0  
I l e  C y s  T h r  L e u  P r o  A s p  L y s  G l u  L y s  Gln I l e  L y s  L y s  G l n  T h r  A l a  
5 1 5  5 2 0  5 2 5  
L e u  A l a  G l u  L e u  V a l  L y s  His L y s  P r o  L y s  A l a  T b r  G l u  A s p  G l n  L e u  




L y s  T h r  V a l  M e t  G l y  A s p  P h c  A l a  G l n  P h e  V a l  A s p  L y s  C y s  C y s  L y s  
5 4 5  5 5 0  5 5 5  5 6 0  
A l a  A l a  A s p  L y s  A s p  A s n  C y s  P h c  A l a  T h r  G l u  G l y  P r o  A s n  L e u  V a l  
5 6 5  5 7 0  5 7 5  
A l a  A r g  S c r  L y s  G l u  A l a  L e u  A l a  
5 8 0  
( 2 ) I N F O M I O N  FOR SEQ ID NO 8 
( I )SEQVENCECHARACTWSTfCS 
( A  )LENGTH 579amunoaolds 
( B )TYPE smmoacid 
( D  )TopOLoGY bmar 
( I I )MOLECULETYPE protein 
( i i i )HypoIwFnCAL:NO 
( i v jANTI-SENSE:NO 
( v ) FRAGMFJiTTYPE: N-tuminal 
( x i j SEQUENCE DESCRIF'TION SEQ ID N O 8  
V a l  A s p  His His L y s  His I l e  A l a  A s p  M e t  T y r  A s n  L e u  L e u  T h r  G l u  
1 5 1 0  1 5  
A r g  T h r  P h c  L y s  G l y  L e u  T h r  L e u  A l a  I l e  V a l  S c r  G l n  A s n  L e u  G l n  
2 0  2 5  3 0  
L y s  C y s  S e r  L e u  G l u  G l u  L e u  S c r  L y s  L e u  V a l  A s n  G l u  I l c  A s n  A s p  
3 5  4 0  4 5  
P h c  A l a  L y s  S c r  C y s  T b r  G l y  A s n  A s p  L y s  T h r  P r o  G l u  C y s  G l u  L y s  
5 0  5 5  6 0  
P r o  I l c  G l y  T h r  L e u  P b c  T y r  A s p  L y s  L e u  C y s  A l a  A s p  P r o  L y s  V a l  
6 5  7 0  7 5  8 0  
G l y  V a l  A s n  T y r  G l u  T r p  S c r  L y s  G l u  C y s  C y s  S c r  L y s  G l n  A s p  P r o  
8 5  9 0  9 5  
G l u  A r g  A l a  G l n  C y s  P b c  A r g  A l a  His A r g  V a l  P h c  G l u  His A s n  P r o  
1 0 0  1 0 5  1 1 0  
V a l  A r g  P r o  L y s  P r o  G l u  G l u  T h r  C y s  A l a  L e u  P h c  L y s  G l u  His P r o  
1 1 5  1 2 0  1 2 5  
A s p  A s p  L e u  L e u  S e r  A l a  P b c  I I e  His G l u  G l u  A l a  A r g  A s n  His P r o  
1 3 0  1 3 5  1 4 0  
A s p  L e u  T y r  P r o  P r o  A l a  V a l  L e u  L e u  L e u  T h r  G l n  G l n  T y r  G l y  L y s  
1 4 5  1 5 0  1 5 5  1 6 0  
L e u  V a l  G l u  His C y s  C y s  Glu G l u  G l u  A s p  L y s  A s p  L y s  C y s  P h c  A l a  
1 6 5  1 7 0  1 7 5  
G l u  L y s  M e t  L y s  G l u  L e u  M e t  L y s  His S c r  His S c r  1 1 s  G l u  A s p  L y s  
1 8 0  1 8 5  1 9 0  
G l n  L y s  His P h c  C y s  T r p  I I c  V a l  A s n  A s n  T y r  P r o  G l u  A r g  V a l  I I c  
1 9 5  2 0 0  2 0 5  
L y s  A l a  L e u  A s n  L e u  A l a  A r g  V a l  S c r  His A r g  T y r  P r o  L y s  P r o  A s p  
2 1 0  2 1 5  2 2 0  
P h c  L y s  L e u  A l a  His L y s  P b e  T h r  G l u  G l u  T b r  T h r  His P h c  I l c  L y s  
2 2 5  2 3 0  2 3 5  2 4 0  
A s p  C y 3  C y s  His G l y  A s p  M e t  P h e  G l u  C y s  M e t  T h r  G l u  A r g  L e u  G l u  
2 4 5  2 5 0  2 5 5  
L e u  S e r  G l u  His T h r  C y s  G l n  His L y s  A s p  G l u  L e u  S c r  T h r  L y s  L e u  
2 6 0  2 6 5  2 7 0  




2 7 5  2 8 0  2 8 5  
T h r  L e u  F l u  A s n  A s p  A s p  V a l  P r o  A l a  G l u  L c u  S c r  L y s  P r o  I l c  T ~ I  
2 9 0  2 9 5  3 0 0  
G l u  P h c  T h r  G l u  A s p  P r o  His V a l  C y s  G l n  L y s  T y r  A l a  G l u  A s n  L y s  
3 0 5  3 1 0  3 1 5  3 2 0  
S c r  P h c  L e u  G l u  I l c  S c r  P r o  T r p  G l n  S c r  G l n  G l u  T h r  P r o  G l u  L e u  
3 2 5  3 3 0  3 3 5  
S c r  G l u  G l n  P h c  L c u  L c u  Gln S c r  A l a  L y s  G l u  T y r  G l u  S c r  L e u  L c u  
3 4 0  3 4 5  3 5 0  
A s n  L y s  C y s  C y s  P b c  S c r  A s p  A s n  P r o  P r o  G l u  C y s  T y r  L y s  A s p  G l y  
3 5 5  3 6 0  3 6 5  
A l a  A s p  A r g  P h c  Met A s n  G l u  A l a  L y s  G l u  A r g  P h c  A l a  T y r  L c u  L y s  
3 7 0  3 7 5  3 8 0  
G l n  A s n  C y s  A s p  I l c  L c u  His G l u  His G l y  G l u  T y r  L e u  P h c  G l u  A s n  
3 8 5  3 9 0  3 9 5  4 0 0  
G l u  L C U  L c u  I I c  A r g  T y r  T h r  L y s  L y s  Met P r o  G l n  V a l  S c r  A s p  G l u  
4 0 5  4 1 0  4 1 5  
T h r  L c u  I I c  G l y  I l c  A l a  His G l n  Mct A l a  A s p  I l c  G l y  G l u  His C y s  
4 2 0  4 2 5  4 3 0  
C y s  A l a  V a l  P r o  G I u  A s n  Gln A r g  Mct P r o  C y s  A l a  G l u  G l y  A s p  L c u  
4 3 5  4 4 0  4 4 5  
T h r  I l e  L e u  I l c  G l y  L y s  Mct C y s  G l u  A r g  G l n  L y s  L y s  T h r  P h e  1 1 s  
4 5 0  4 5 5  4 6 0  
A s n  A s n  His V a l  A l a  His C y s  C y s  T h r  A s p  S c r  T y r  S c r  G l y  Met A r g  
4 6  5 4 7 0  4 7  5 4 8 0  
S c r  C y r  P h c  T h r  A l a  L e u  G l y  P r o  A s p  G l u  A s p  T y r  V a l  P r o  P r o  P r o  
4 8 5  4 9 0  4 9 5  
V a l  T h r  A s p  A s p  T h r  P h c  His P h c  A s p  A s p  L y s  I l c  C y s  T h r  A l a  A s n  
5 0 0  5 0 5  5 1 0  
A s p  L y s  G l u  L y s  G l n  His 1 1 s  L y s  G l n  L y s  P h c  L c u  V a l  L y s  L e u  I l c  
5 1 5  5 2 0  5 2 5  
L y s  V a l  S c r  P r o  L y s  L c u  G l u  L y s  A s n  His I I c  A s p  G l u  T r p  L e u  L c u  
5 3 0  5 3 5  5 4 0  
G l u  P h c  L e u  L y s  Mct V a l  G l n  L y s  C y s  C y s  T h r  A l a  A s p  G l u  His Gln 
5 4 5  5 5 0  5 5 5  5 6 0  
P r o  C y s  P h c  A s p  T h r  G l u  L y s  P r o  V a l  L e u  I I c  G l u  His C y s  Gln L y s  
5 6 5  5 7 0  5 7 5  
L e u  His P r o  
( 2 ) INFORMMION FOR SEQ ID N O 9  
( i )SEQUENCECHAR4CIERIISTICS 
( A  )LENa'IH:mamimacids 
( D  )MrnLG€iY:lina 
( B  )TYF'E:aninoacid 
( i i )MOLEK!ULETYPE:p.otdn 
( i i i )HYPOTHETICAL:NO 
( i v )ANTISENSE: NO 
( v ) FRAOMENT TYPE: N-tcrminal 
(xi ~ S l 2 Q U E N C E D B ~ O N : S I ? Q I D N O S ?  
S e r  G l n  A l a  G l n  A s n  G l n  I l c  C y s  T b r  I l c  P b c  T h r  G l u  A l a  L y s  G l u  
1 5 1 0  1 5  





2 0  2 5  3 0  
A s p  S c r  T h r  L e u  G l y  A s p  L e u  V a l  P r o  L c u  I I c  A l a  G l u  A l a  L e u  A l a  
3 5  4 0  4 5  
M c f  G l y  V a l  L y s  C y s  C y s  S e r  A s p  T h r  P r o  P r o  G l u  A s p  C y s  G l u  A r g  
5 0  5 5  6 0  
A s p  V a l  A l a  A s p  L e u  P h c  G l o  S c r  A l a  V a l  C y s  S c r  S c r  Glu T b r  L e u  
6 5  7 0  7 5  8 0  
V a l  G l u  L y s  A s n  A s p  L e u  L y s  Met C y s  C y s  G l u  L y s  T h r  A l a  A l a  G l u  
8 5  9 0  9 5  
A r g  T b r  His C y s  P b c  V a l  A s p  His L y s  A l a  L y r  I l c  P r o  A r g  A s p  L e u  
1 0 0  1 0 5  1 1 0  
S c r  L e u  L y s  A l a  G l u  L e u  P r o  A l a  A l a  A s p  G l n  C y s  G l u  A s p  P h e  L y s  
I 1 5  1 2 0  I 2 5  
L y s  A s p  His L y s  A l a  P h c  V a l  G l y  A r g  P b e  I l c  P h c  L y s  P h c  S e r  L y s  
1 3 0  1 3 5  1 4 0  
S e r  A s n  P r o  Met L e u  P r o  P r o  His V a l  V a l  L e u  A l e  I l c  A l a  L y s  G l y  
1 4 5  I 5 0  I 5 5  1 6 0  
T y r  G l y  G l u  V a l  L e u  T b r  T h r  C y s  C y s  G l y  G l u  A l a  G l u  A l a  G l n  T b r  
1 6 5  1 7 0  1 7 5  
C y s  P h c  A s p  T h r  L y s  L y s  A l a  T h r  P h e  G I n  His A l a  V a l  Met L y s  A r g  
1 8 0  1 8 5  I 9 0  
V a l  A l a  G l u  L e u  A r g  S c r  L e u  C y s  I l c  V a l  His L y s  L y s  T y r  G l y  A s p  
1 9 5  2 0 0  2 0 5  
A r g  V a l  V a l  L y s  A l a  L y s  L y s  L e u  V a l  0111 T y r  S c r  G l n  L y s  Mct P r o  
2 1 0  2 1 5  2 2 0  
G l n  A l a  S c r  P b c  G l n  G l u  Mct G l y  G l y  Met V a l  A s p  L y s  I l c  V a l  A l a  
2 2 5  2 3 0  2 3 5  2 4 0  
T b r  V a l  A l a  P r o  C y s  C y s  S c r  G i y  A s p  Met V a l  T b r  C y s  Met L y s  G l u  
2 4 5  2 5 0  2 5 5  
A r g  L y s  T b r  L c u  V a l  A s p  G l u  V a l  C y s  A l a  A s p  G l u  S c r  V a l  L e u  S c r  
2 6 0  2 6 5  2 7 0  
A r g  A l a  A l a  G l y  L c u  S c r  A l a  C y s  C y s  L y s  G l u  A s p  A l a  V a l  His A r g  
2 7 5  2 8 0  2 8 5  
G l y  S c r  C y s  V a l  GLu A l a  M c t  L y s  P r o  A s p  P r o  L y s  P r o  A s p  G l y  L e u  
2 9 0  2 9 5  3 0 0  
S c r  G l u  His T y r  A s p  1 1 s  His A l a  A s p  I l c  A l a  A l a  V a l  C y s  G l n  T b r  
3 0 5  3 1 0  3 1 5  3 2 0  
P h c  T h r  L y s  P r o  T h r  A s p  V a l  A l a  Mct G l y  L y s  L c u  V a l  T y r  G l u  I l c  
3 2 5  3 3 0  3 3 5  
S c r  V a l  A r g  His P r o  G l u  S c r  S c r  G l n  G l n  V a l  I l c  L e u  A r g  P h c  A l a  
3 4 0  3 4 5  3 5 0  
L y s  G l u  A l a  G l u  G l n  A l a  L e u  L c u  G l n  C y s  C y s  A s p  Met G l u  A s p  His 
3 5 5  3 6 0  3 6 5  
A l a  GLu C y s  V a l  L y s  T h r  A l a  L c u  A l a  G l y  S e r  A s p  1 1 s  A s p  L y s  L y s  
3 7 0  3 7 5  3 8 0  
I I c  T h r  A s p  G l u  T h r  A s p  T y r  T y r  L y s  L y s  Met C y s  A l a  A l a  G l u  A l a  
3 8 5  3 9 0  3 9 5  4 0 0  
A l a  V a l  S c r  A s p  A s p  S c r  P h c  G l u  L y s  S c r  Met Mct V a l  Tyr T y r  T h r  
4 0 5  4 1 0  4 1 5  
A r g  I l c  Mct P r o  G l n  A l a  S c r  P b c  A s p  G l n  L e u  His Met V a l  S c r  G l n  
4 2 0  4 2 5  4 3 0  
T b r  V a l  His A s p  V a l  L e u  His A l a  C y s  C y s  L y s  A s p  G l u  G l n  G l y  His 





P h e  V a l  L e u  P r o  C y s  A l a  G l u  GIu L y s  L e u  T h r  A s p  A l a  I l c  A s p  A l a  
4 5 0  4 5  5 4 6 0  
T b r  C y s  A s p  A s p  T y r  A s p  P r o  S e r  S e r  I I e  A s n  P r o  His I l e  A l a  His 
4 6 5  4 7 0  4 7 5  4 8 0  
C y s  C y s  A s n  G l n  S e r  T y r  S e r  M e t  A r g  A r g  His C y s  I l c  L e u  A l a  I l e  
4 8 5  4 9 0  4 9 5  
G l n  P r o  A s p  T h r  G l u  P h c  T h r  P r o  P r o  G l u  L e u  A s p  A l a  S e r  S c r  P h e  
5 0 0  5 0 5  5 1 0  
His M e t  G l y  P r o  G l u  L e u  C y s  T h r  L y s  A s p  S c r  L y s  A s p  L e u  L e u  L e u  
5 1 5  5 2 0  5 2 5  
S e r  G l y  L y s  L y s  L e u  L e u  T y r  G l y  V a l  V a l  A r g  His L y s  T b r  T h r  I l c  
5 3 0  5 3 5  5 4 0  
T b r  G l u  A s p  His L e u  L y s  T h r  I l e  S c r  T h r  L y s  T y r  H I S  T b r  M e t  L y s  
5 4 5  5 5 0  5 5 5  5 6 0  
G l u  L y s  C y s  C y s  A l a  A l a  G l u  A s p  G l n  A l a  A l a  Cys P h c  T h r  G l u  G I u  
5 6 5  5 7 0  5 7 5  
A l a  P r o  L y s  L e u  V a l  S e r  G l u  S e r  A l a  G l u  L e u  V a l  L y s  V a l  
5 8 0  5 8 5  5 9 0  
25 
What is claimed is: 
1. A serum albumin protein fragment consisting of at least 
one serum albumin binding region selected from the group 
consisting of binding region subdo& and binding 
region subdomain IIIA. 
2. A serum albumin protein fragment according to claim 
1 wherein the albumin binding region consists of 
binding region subdomain IIA. 
3. A serum albumin protein fragment according to claim 
1 wherein the serum albumin binding region consists of 35 
binding region subdomain IIIA. 
1 wherein the serum albumin binding region consists of 
binding region subdomains IIA. IIB and IUA. 
1 wherein the serum albumin binding region is a binding 
region of a serum albumin selected from the group consist- 
ing of human. bovine, equine. ovine. rat. frog. sheep. 
6. A serum albumin protein fragment according to claim 
5 wherein the serum albumin binding region is a human 
serum albumin binding region. 
7. A serum albumin protein fragment according to Claim 
30 5 wherein the serum albumin binding region is an equine 
8. A serum albumin protein fragment according to claim 
5 wherein the serum albumin binding region is a bovine 
Serum 
9. A serum albumin protein fragment according to claim 
wherein the Serum albumin binding region consists of SEQ 
albumin binding region- 
binding 
ID NO: 1. 
8. wherein the SeNm albumin binding region consists of 
SEQ ID NO:2. 
ll. A serum albumin protein fragment according to claim 
wherein the serum albumin binding region consists of 
4' A serum prdein fragment according to 10. A s e ~ m  albumin protein fragment according to claim 
5. A serum albumin protein fragment according to claim 40 
amino acids to 494 of sEQ ID NO:4. 
salmon. mouse. and sea lamprey serum albumin proteins. * * * * *  
